Crucell Holland BV
Quick facts
Marketed products
- Engerix B · Immunology
Engerix B is a recombinant hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg). - HAVpur Junior · Immunology / Infectious Disease
HAVpur Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. - Inflexal V
- Quinvaxem/Tritanrix · Immunology
Quinvaxem/Tritanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b.
Phase 3 pipeline
- Ad26.ZEBOV-Batch #1 · Immunology / Infectious Disease
Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection. - Ad26.ZEBOV-Batch #2 · Immunology / Infectious Disease
Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection. - Ad26.ZEBOV-Batch #3 · Immunology / Infectious Disease
Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein, designed to elicit immune responses against Ebola virus. - Epaxal · Other
- Havrix 720 · Immunology / Infectious Disease
Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. - HepavaxGene (thiomersal free) · Immunology / Infectious Disease
HepavaxGene is a recombinant hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen. - Quinvaxem in single dose vials · Immunology / Infectious Disease
Quinvaxem is a pentavalent conjugate vaccine that provides immunization against five bacterial pathogens by stimulating antibody and cellular immune responses. - Quinvaxem in Uniject · Immunology
Quinvaxem is a pentavalent conjugate vaccine that provides immunization against Haemophilus influenzae type b, diphtheria, tetanus, pertussis, and hepatitis B through stimulation of humoral and cellular immune responses.
Phase 2 pipeline
- CL184
CL184 is a vaccine that targets an unspecified pathogen. - Epaxal 0.25 mL
- HRIG
- Rabies virus-specific monoclonal antibodies
Phase 1 pipeline
- Ad26.RSV.FA2
- Ad35.RSV.FA2
- Commercial vaccine 1
- Commercial vaccine 2
- MVA Mosaic
- Quadrivalent virosomal influenza vaccine
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: